NASDAQ:TORC - resTORbio Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$9.14 +0.11 (+1.22 %)
(As of 05/27/2018 11:29 AM ET)
Previous Close$9.14
Today's Range$8.93 - $9.28
52-Week Range$7.55 - $21.10
Volume73,053 shs
Average Volume144,050 shs
Market Capitalization$256.34 million
P/E Ratio-1.09
Dividend YieldN/A
BetaN/A

About resTORbio (NASDAQ:TORC)

resTORbio logoresTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts. resTORbio, Inc. is a subsidiary of PureTech Health plc.

Receive TORC News and Ratings via Email

Sign-up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TORC
CUSIPN/A
Phone857-315-5521

Debt

Debt-to-Equity RatioN/A
Current Ratio20.03
Quick Ratio20.04

Price-To-Earnings

Trailing P/E Ratio-1.09
Forward P/E Ratio-5.22
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.65 per share
Price / Book1.97

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees7
Outstanding Shares28,050,000

resTORbio (NASDAQ:TORC) Frequently Asked Questions

What is resTORbio's stock symbol?

resTORbio trades on the NASDAQ under the ticker symbol "TORC."

How were resTORbio's earnings last quarter?

resTORbio (NASDAQ:TORC) announced its quarterly earnings results on Thursday, May, 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.20. View resTORbio's Earnings History.

What price target have analysts set for TORC?

4 analysts have issued 1 year price targets for resTORbio's shares. Their forecasts range from $23.00 to $36.00. On average, they expect resTORbio's share price to reach $29.25 in the next twelve months. View Analyst Ratings for resTORbio.

Are investors shorting resTORbio?

resTORbio saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 786,110 shares, an increase of 28.2% from the March 30th total of 613,293 shares. Based on an average daily trading volume, of 153,253 shares, the short-interest ratio is currently 5.1 days. Currently, 6.8% of the company's shares are sold short.

Who are some of resTORbio's key competitors?

Who are resTORbio's key executives?

resTORbio's management team includes the folowing people:
  • Mr. Chen Schor, Co-Founder, Pres, CEO & Director (Age 46)
  • Dr. Joan Mannick M.D., Co-Founder & Chief Medical Officer (Age 59)
  • Mr. John J. McCabe CPA, CPA, VP of Fin. & Principal Accounting Officer (Age 50)
  • Dr. Abdellah Sentissi Ph.D., Head of CMC & Pharmaceutical Devel. (Age 68)
  • Ms. Susan Stewart J.D., Head of Regulatory Affairs

When did resTORbio IPO?

(TORC) raised $86 million in an initial public offering on Friday, January 26th 2018. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Has resTORbio been receiving favorable news coverage?

News articles about TORC stock have been trending somewhat positive on Sunday, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. resTORbio earned a coverage optimism score of 0.09 on Accern's scale. They also assigned media headlines about the company an impact score of 46.06 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are resTORbio's major shareholders?

resTORbio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (1.96%), Artal Group S.A. (1.60%), BlackRock Inc. (1.06%), Rock Springs Capital Management LP (0.98%), JPMorgan Chase & Co. (0.59%) and Northern Trust Corp (0.24%). Company insiders that own resTORbio stock include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Institutional Ownership Trends for resTORbio.

Which institutional investors are buying resTORbio stock?

TORC stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Artal Group S.A., BlackRock Inc., Rock Springs Capital Management LP, JPMorgan Chase & Co., Northern Trust Corp, Schwab Charles Investment Management Inc. and Citadel Advisors LLC. Company insiders that have bought resTORbio stock in the last two years include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Insider Buying and Selling for resTORbio.

How do I buy shares of resTORbio?

Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is resTORbio's stock price today?

One share of TORC stock can currently be purchased for approximately $9.14.

How big of a company is resTORbio?

resTORbio has a market capitalization of $256.34 million. The company earns $-33,770,000.00 in net income (profit) each year or ($8.42) on an earnings per share basis. resTORbio employs 7 workers across the globe.

How can I contact resTORbio?

resTORbio's mailing address is 500 BOYLSTON STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5521.


MarketBeat Community Rating for resTORbio (TORC)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  17 (Vote Outperform)
Underperform Votes:  13 (Vote Underperform)
Total Votes:  30
MarketBeat's community ratings are surveys of what our community members think about resTORbio and other stocks. Vote "Outperform" if you believe TORC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TORC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

resTORbio (NASDAQ:TORC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for resTORbio in the last 12 months. Their average twelve-month price target is $29.25, suggesting that the stock has a possible upside of 220.02%. The high price target for TORC is $36.00 and the low price target for TORC is $23.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.25$29.25$29.25N/A
Price Target Upside: 220.02% upside55.92% upside55.92% upsideN/A

resTORbio (NASDAQ:TORC) Consensus Price Target History

Price Target History for resTORbio (NASDAQ:TORC)

resTORbio (NASDAQ:TORC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/20/2018Leerink SwannInitiated CoverageOutperform ➝ Outperform$36.00HighView Rating Details
2/20/2018WedbushInitiated CoverageOutperform$30.00HighView Rating Details
2/20/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$23.00HighView Rating Details
2/20/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$28.00HighView Rating Details
(Data available from 5/27/2016 forward)

Earnings

resTORbio (NASDAQ:TORC) Earnings History and Estimates Chart

Earnings by Quarter for resTORbio (NASDAQ:TORC)

resTORbio (NASDAQ:TORC) Earnings Estimates

2018 EPS Consensus Estimate: ($1.45)
2019 EPS Consensus Estimate: ($2.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.29)($0.29)($0.29)
Q2 20181($0.34)($0.34)($0.34)
Q3 20181($0.39)($0.39)($0.39)
Q4 20181($0.43)($0.43)($0.43)
Q1 20191($0.50)($0.50)($0.50)
Q2 20191($0.55)($0.55)($0.55)
Q3 20191($0.59)($0.59)($0.59)
Q4 20191($0.60)($0.60)($0.60)

resTORbio (NASDAQ TORC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018Q1 2018($0.26)($0.46)ViewN/AView Earnings Details
3/29/2018Q4($1.03)($5.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

resTORbio (NASDAQ:TORC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

resTORbio (NASDAQ TORC) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 39.25%
Insider Trading History for resTORbio (NASDAQ:TORC)
Institutional Ownership by Quarter for resTORbio (NASDAQ:TORC)

resTORbio (NASDAQ TORC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Chen SchorInsiderBuy2,000$8.95$17,900.00View SEC Filing  
4/10/2018Chen SchorInsiderBuy2,000$8.46$16,920.00View SEC Filing  
1/30/2018Orbimed Advisors LlcDirectorBuy533,333$15.00$7,999,995.00View SEC Filing  
1/30/2018Puretech Health LlcMajor ShareholderBuy233,333$15.00$3,499,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

resTORbio (NASDAQ TORC) News Headlines

Source:
DateHeadline
resTORbio (TORC) and Its Peers Head-To-Head ReviewresTORbio (TORC) and Its Peers Head-To-Head Review
www.americanbankingnews.com - May 26 at 7:19 PM
resTORbio to Host Key Opinion Leader Symposium on TORC1 InhibitionresTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition
finance.yahoo.com - May 23 at 9:13 AM
Reviewing resTORbio (TORC) and Its PeersReviewing resTORbio (TORC) and Its Peers
www.americanbankingnews.com - May 18 at 11:24 PM
Zacks: Brokerages Anticipate resTORbio (TORC) to Announce -$0.42 EPSZacks: Brokerages Anticipate resTORbio (TORC) to Announce -$0.42 EPS
www.americanbankingnews.com - May 17 at 1:25 AM
 resTORbio (TORC) Receives Consensus Rating of "Strong Buy" from Analysts resTORbio (TORC) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - May 13 at 1:41 PM
Head to Head Survey: Supernus Pharmaceuticals (SUPN) versus resTORbio (TORC)Head to Head Survey: Supernus Pharmaceuticals (SUPN) versus resTORbio (TORC)
www.americanbankingnews.com - May 12 at 9:05 PM
Critical Contrast: resTORbio (TORC) & The CompetitionCritical Contrast: resTORbio (TORC) & The Competition
www.americanbankingnews.com - May 12 at 5:11 PM
resTORbio (TORC) Issues  Earnings ResultsresTORbio (TORC) Issues Earnings Results
www.americanbankingnews.com - May 11 at 2:22 PM
resTORbio Reports First Quarter 2018 Financial ResultsresTORbio Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 11 at 8:31 AM
resTORbio to Present at the Bank of America Merrill Lynch 2018 Health Care ConferenceresTORbio to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 10 at 8:30 AM
Topline 16-week data now expected in the third quarter of 2018Topline 16-week data now expected in the third quarter of 2018
globenewswire.com - May 9 at 3:24 PM
ResTORbio completes dosing in mid-stage study of RTB101 in respiratory tract infections; data readout next quarter; shares up 4%ResTORbio completes dosing in mid-stage study of RTB101 in respiratory tract infections; data readout next quarter; shares up 4%
seekingalpha.com - May 9 at 3:24 PM
resTORbio Completes Dosing of Patients in Phase 2b Study to Reduce the Incidence of Respiratory Tract Infections in the ElderlyresTORbio Completes Dosing of Patients in Phase 2b Study to Reduce the Incidence of Respiratory Tract Infections in the Elderly
finance.yahoo.com - May 9 at 8:38 AM
resTORbio (TORC) & Its Competitors Head-To-Head SurveyresTORbio (TORC) & Its Competitors Head-To-Head Survey
www.americanbankingnews.com - May 4 at 5:19 PM
ValuEngine Upgrades resTORbio (TORC) to HoldValuEngine Upgrades resTORbio (TORC) to Hold
www.americanbankingnews.com - May 2 at 3:48 PM
resTORbio to Present at the Deutsche Bank 43rd Annual Health Care ConferenceresTORbio to Present at the Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - May 2 at 8:22 AM
resTORbio (TORC) Expected to Announce Earnings of -$0.29 Per ShareresTORbio (TORC) Expected to Announce Earnings of -$0.29 Per Share
www.americanbankingnews.com - April 29 at 11:10 AM
Brokerages Expect resTORbio (TORC) to Post ($0.29) EPSBrokerages Expect resTORbio (TORC) to Post ($0.29) EPS
www.americanbankingnews.com - April 28 at 7:52 AM
resTORbio (TORC) Short Interest UpdateresTORbio (TORC) Short Interest Update
www.americanbankingnews.com - April 28 at 2:28 AM
resTORbio (TORC) Insider Chen Schor Buys 2,000 SharesresTORbio (TORC) Insider Chen Schor Buys 2,000 Shares
www.americanbankingnews.com - April 17 at 10:14 AM
Zacks: Analysts Set $29.25 Target Price for resTORbio (TORC)Zacks: Analysts Set $29.25 Target Price for resTORbio (TORC)
www.americanbankingnews.com - April 13 at 3:29 AM
Thursday 4/12 Insider Buying Report: ETM, TORCThursday 4/12 Insider Buying Report: ETM, TORC
www.nasdaq.com - April 12 at 3:21 PM
-$0.29 Earnings Per Share Expected for resTORbio (TORC) This Quarter-$0.29 Earnings Per Share Expected for resTORbio (TORC) This Quarter
www.americanbankingnews.com - April 12 at 1:25 PM
BioSci Rounds Report: Improving Fundamentals To Catapult Omeros And RestorbioBioSci Rounds Report: Improving Fundamentals To Catapult Omeros And Restorbio
seekingalpha.com - April 12 at 7:54 AM
Wedbush Weighs in on resTORbios Q1 2018 Earnings (TORC)Wedbush Weighs in on resTORbio's Q1 2018 Earnings (TORC)
www.americanbankingnews.com - April 12 at 7:25 AM
resTORbio (TORC) Insider Chen Schor Acquires 2,000 SharesresTORbio (TORC) Insider Chen Schor Acquires 2,000 Shares
www.americanbankingnews.com - April 11 at 10:16 AM
resTORbio (TORC) Releases  Earnings Results, Misses Estimates By $4.08 EPSresTORbio (TORC) Releases Earnings Results, Misses Estimates By $4.08 EPS
www.americanbankingnews.com - March 30 at 9:16 AM
resTORbio Reports Fourth Quarter and Full Year 2017 Financial ResultsresTORbio Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 30 at 7:34 AM
A Cambridge biotech is the worst-performing IPO so far this year nationallyA Cambridge biotech is the worst-performing IPO so far this year nationally
finance.yahoo.com - March 29 at 3:20 PM
Analysts Expect resTORbio, Inc. (TORC) to Announce ($1.03) Earnings Per ShareAnalysts Expect resTORbio, Inc. (TORC) to Announce ($1.03) Earnings Per Share
www.americanbankingnews.com - March 29 at 10:29 AM
resTORbio, Inc. (TORC) Expected to Post Earnings of -$1.03 Per ShareresTORbio, Inc. (TORC) Expected to Post Earnings of -$1.03 Per Share
www.americanbankingnews.com - March 26 at 1:06 PM
resTORbio Announces Formation of Clinical Advisory BoardresTORbio Announces Formation of Clinical Advisory Board
finance.yahoo.com - March 19 at 3:18 PM
Analysts Anticipate resTORbio, Inc. (TORC) to Post ($1.03) Earnings Per ShareAnalysts Anticipate resTORbio, Inc. (TORC) to Post ($1.03) Earnings Per Share
www.americanbankingnews.com - March 14 at 3:26 AM
-$1.03 EPS Expected for resTORbio, Inc. (TORC) This Quarter-$1.03 EPS Expected for resTORbio, Inc. (TORC) This Quarter
www.americanbankingnews.com - March 9 at 12:45 PM
Zacks: resTORbio, Inc. (TORC) Given Average Rating of "Strong Buy" by BrokeragesZacks: resTORbio, Inc. (TORC) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - March 8 at 3:28 AM
Brokerages Anticipate resTORbio, Inc. (TORC) to Post ($1.03) Earnings Per ShareBrokerages Anticipate resTORbio, Inc. (TORC) to Post ($1.03) Earnings Per Share
www.americanbankingnews.com - March 2 at 7:16 PM
resTORbio, Inc.s Quiet Period Set To End  on March 7th (NASDAQ:TORC)resTORbio, Inc.'s Quiet Period Set To End on March 7th (NASDAQ:TORC)
www.americanbankingnews.com - February 28 at 1:08 AM
Brokerages Expect resTORbio, Inc. (TORC) to Post ($1.03) Earnings Per ShareBrokerages Expect resTORbio, Inc. (TORC) to Post ($1.03) Earnings Per Share
www.americanbankingnews.com - February 25 at 3:30 PM
Brokers Set Expectations for resTORbio, Inc.s FY2017 Earnings (TORC)Brokers Set Expectations for resTORbio, Inc.'s FY2017 Earnings (TORC)
www.americanbankingnews.com - February 22 at 6:46 AM
Zacks: resTORbio, Inc. (TORC) Given $29.25 Consensus Target Price by BrokeragesZacks: resTORbio, Inc. (TORC) Given $29.25 Consensus Target Price by Brokerages
www.americanbankingnews.com - February 21 at 9:52 AM
Four Reasons Behind BofAs Bullish Restorbio InitiationFour Reasons Behind BofA's Bullish Restorbio Initiation
finance.yahoo.com - February 21 at 6:13 AM
resTORbio (TORC) Now Covered by Evercore ISIresTORbio (TORC) Now Covered by Evercore ISI
www.americanbankingnews.com - February 20 at 9:30 PM
resTORbio to Present at the 2018 RBC Capital Markets Global Healthcare ConferenceresTORbio to Present at the 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 20 at 3:17 PM
resTORbio (TORC) Earns Buy Rating from Analysts at Bank of AmericaresTORbio (TORC) Earns Buy Rating from Analysts at Bank of America
www.americanbankingnews.com - February 20 at 3:07 PM
resTORbio (TORC) Research Coverage Started at Leerink SwannresTORbio (TORC) Research Coverage Started at Leerink Swann
www.americanbankingnews.com - February 20 at 11:30 AM
resTORbio (TORC) Now Covered by Analysts at WedbushresTORbio (TORC) Now Covered by Analysts at Wedbush
www.americanbankingnews.com - February 20 at 7:34 AM
resTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesresTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - February 5 at 8:39 AM
Insider Buying: resTORbio, Inc. (TORC) Major Shareholder Purchases 233,333 Shares of StockInsider Buying: resTORbio, Inc. (TORC) Major Shareholder Purchases 233,333 Shares of Stock
www.americanbankingnews.com - January 31 at 12:20 AM
Insider Buying: resTORbio, Inc. (TORC) Director Purchases 533,333 Shares of StockInsider Buying: resTORbio, Inc. (TORC) Director Purchases 533,333 Shares of Stock
www.americanbankingnews.com - January 30 at 9:18 PM
resTORbio (TORC) Announces January 26th IPOresTORbio (TORC) Announces January 26th IPO
www.americanbankingnews.com - January 18 at 1:30 AM

SEC Filings

resTORbio (NASDAQ:TORC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

resTORbio (NASDAQ TORC) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.